ストックスクリーナーアプリを入手
1.80
7.69%
-0.15
アフターアワーズ：
1.79
-0.01
-0.56%
MAIA Biotechnology Inc (MAIA) 最新ニュース
MAIA Biotechnology Reports Positive Phase 2 Trial Results - TipRanks
Why Is MAIA Biotechnology Stock Trading Higher On Thursday?MAIA Biotechnology (AMEX:MAIA) - Benzinga
MAIA Biotechnology's Promising Results in Lung Cancer Trial | MA - GuruFocus
MAIA Biotechnology Says New Responder In Non-Small Cell Lung Cancer Phase 2 Clinical Trial - marketscreener.com
MAIA Biotechnology Announces New Responder in Non-Small Cell Lung Cancer Phase 2 Clinical Trial - Business Wire
MAIA Biotechnology Announces Positive Efficacy Update for Phase 2 THIO-101 Clinical Trial in Non-Small Cell Lung Cancer - BioSpace
MAIA Biotechnology Reports Promising Results from THIO-101 Phase 2 Trial | MAIA Stock News - GuruFocus
Maia Biotechnology Says Ateganosine Treatment Extends Median Overall Survival in Lung Cancer Study - marketscreener.com
Maia Biotechnology stock rises following positive trial results By Investing.com - Investing.com Canada
Maia Biotechnology stock rises following positive trial results - Investing.com Australia
MAIA Biotechnology Showcases Promising THIO-101 Trial Data - TipRanks
MAIA Biotechnology Announces Private Placement Agreement - TipRanks
MAIA Biotechnology (NYSEAMERICAN:MAIA) Trading 4.1% Higher – Still a Buy? - Defense World
MAIA Biotechnology secures $669,500 in private placement By Investing.com - Investing.com South Africa
MAIA Biotechnology Announces Private Placement of Approximately $669,500 - BioSpace
MAIA Biotechnology, Inc. (MAIA) Raises $695K in Private Placement to Advance Cancer Trial - Yahoo
CORRECTING and REPLACING MAIA Biotechnology Announces Private Placement of Approximately $695,000 - BioSpace
MAIA Biotechnology secures $669,500 in private placement - Investing.com
MAIA Biotechnology doubles authorized shares - Investing.com Australia
MAIA Biotechnology doubles authorized shares By Investing.com - Investing.com South Africa
MAIA Biotechnology Increases Authorized Common Stock Shares - TipRanks
MAIA Biotechnology Approves Key Changes at Annual Meeting - TipRanks
MAIA Biotechnology Accepted for Poster Presentation at American Society of Clinical Oncology (ASCO) 2025 Annual Meeting - Business Wire
MAIA Biotechnology Announces Director Participation in Recent Private Placement - Business Wire
Best Momentum Stocks to Buy for May 6th - The Globe and Mail
MAIA Biotechnology Raises $1.08M in Private Placement - TipRanks
MAIA Biotechnology launches $1.08M private placement - MSN
CORRECTION: MAIA Biotechnology Announces $1.08 Million Private Placement - Business Wire
MAIA Biotechnology secures $1.08 million in private placement By Investing.com - Investing.com Canada
Maia Biotechnology Announces $1.08 Million Private Placement - marketscreener.com
MAIA Biotechnology secures $1.08 million in private placement - Investing.com
MAIA Biotechnology Raises $1.08M at $1.50 Per Share to Advance Phase II Cancer Trial - Stock Titan
MAIA Biotechnology Announces $1.08 Million Private Placement - Business Wire
MAIAMAIA Biotechnology Inc. Latest Stock News & Market Updates - Stock Titan
MAIA Biotechnology Inc (MAIA) Stock: A 52-Week Tale of Drops and Gains - investchronicle.com
Do investors need to be concerned about MAIA Biotechnology Inc (MAIA)? - uspostnews.com
MAIA Biotechnology Inc: Navigating Market Fluctuations with a 60.66M Market Cap - investchronicle.com
MAIA Biotechnology Inc [MAIA] stock for 50,000 USD was acquired by Guerrero Ramiro - knoxdaily.com
MAIA’s Q2 earnings predictions: What the experts say - uspostnews.com
MAIA Biotechnology (NYSEAMERICAN:MAIA) Trading Up 14.8% – Here’s Why - Defense World
MAIA Biotechnology publishes preclinical data for telomere-targeting THIO dimer - MSN
MAIA stock touches 52-week low at $1.41 amid market challenges - Investing.com India
MAIA Biotechnology- Phase 2 Trial Thio-101 Expansion Underway Potential Filing In 2026 For Accelerated Approval - MarketScreener
MAIA Biotechnology targets 2026 for FDA approval of cancer drug - Investing.com
Breakthrough Cancer Drug Pipeline: MAIA's Telomere-Targeting Therapy Eyes FDA Fast Track - Stock Titan
MAIA Biotechnology CEO Details Anticipated Clinical Milestones for Novel Cancer Immunotherapy in 2025 Letter to Shareholders - Business Wire
MAIA Biotechnology, Inc. (MAIA) Upgraded to Buy: Here's What You Should Know - MSN
1.21%
1.51%
大文字化:
|
ボリューム (24 時間):